

Audrey's Life Science Meeting Picks for March 5, 2017 – May 2017
Complimentary Service of AudreysNetwork.com
March 5, 2017

JLABS, Tuesday Morning, March 7, 2017

Topic: "Value of Biotechnology Business"

Speaker: John Selig | Managing Partner, Mavericks Capital

Date and Time: Tuesday, March 7, 2017, 9:45 am

Agenda:

9:45am | Registration

10:00am | Presentation and Q&A

11:30am | Lunch and Networking

12:00 | Program close

Location: JLABS @ SSF. 329 Oyster Point Blvd - 3rd Floor. South San Francisco, California

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Details and registration at <https://www.eventbrite.com/e/the-value-of-a-biotechnology-business-tickets-29593178995?aff=weekly>

Topic Description

Biotech companies... do you know your worth? The wise startup company plans their exit from the beginning. In order to properly leverage your exit value you need to understand the different valuation methods, how they are used and who is using them.

John Selig, Managing Partner and co-founder of Mavericks Capital, a healthcare investment bank, will guide you through the maze of sunk costs, sum of parts, comparables, Discounted Cash Flow (DTC) and Net Present Value (NPV) to help you increase negotiating leverage and make more informed funding decisions.

Join us for an informative and interactive session.

Topics Covered

The different valuation methodologies and who is using them

Key approaches in funding for life science companies

Planning exit strategies and deal structuring from the outset

How do my expected deal terms relate to my forecast cash flows and how can I use this to make better decisions on licensing timing?

In cooperation with BioPharma Consortium. Visit www.Biopharmaconsortium.com for more information.

Speaker Bio

John advises life science companies on M&A, licensing and financial strategy. He speaks frequently on topics in valuation, deal term benchmarking, and strategy in the life sciences space, including the Valuation and Finance module at BIO's Executive Management Training course for BD professionals each year and the Valuation lecture at Stanford Medical School's Entrepreneurship Program. Prior to joining Maverick's,

John co-lead the Life Sciences Group at Woodside Capital Partners, a boutique investment bank. For the prior 12 years, he advised both Fortune 100 and VC - backed healthcare companies on transaction strategy and valuation at Strategic Decisions Group (SDG), a global management consulting firm, and Keelin Reeds Partners, a life sciences consulting firm. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to provide ongoing support during deal negotiations. Prior to consulting, John was an attorney with Weil, Gotshal and Manges where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa (FINRA 24, 63, 79).

BMES and B2Device Group, Tuesday Evening, March 7, 2017

Event: BMES and B2DG for a Happy Hour
Date and Time: Tuesday, March 7, 2017, 5:00 - 8:00 pm
Location: Campo di Bocce, Fremont, 4020 Technology Pl, Fremont, CA 94538
(510) 651-2500
No membership needed. Please register in advance.
FREE REGISTRATION LINK <https://goo.gl/i5AmGk>
Free Appetizers
No host bar

Event Description

Grow your network and connect with others in the Bay Area-Silicon Valley Biomedical Industry by attending our next Happy Hour.

Brought to you by:

- BMN-logo-color-copy.png
- Fremont.png
- KGI.JPG
- Biocom-logo.JPG
- Bio2Device.jpg
- BMES-SF-Chapter.jpg

UCSC Clinical Trials Course: March 13-17, 2017

Event: Clinical Trials Essentials: An Intensive One-Week Course
Event Dates: Monday March 13- Friday, March 17 2017
03/13/2017 - 8:00am
Event Location: UCSC Ext 3175 Bowers Avenue, Santa Clara

Event Description

The course benefits anyone working in the biopharmaceutical and medical device industries and the biomedical community who is interfacing with or conducting clinical research, including new clinical research associates and study coordinators; medical directors, physicians, nurses, pharmacists, and other health professionals; biomedical scientists; statisticians and database administrators; and business professionals.

Bio2Device Group, Tuesday Evening, March 14, 2017

Topic: "Brink of Catastrophe: Catching Addiction Early"

Speaker: David Deacon, CEO, DxRx Inc

Date and Time: Tuesday, March 14, 2017, 6:00 pm

Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto

Cost:

\$6 - Students/In-transition - Members only

\$11 - Early-bird Registration - Members only

\$20 - Late Registration and Non-Members

\$25 - Walk-ins

Register at www.Bio2DeviceGroup.org

Topic Description

One out of every ten Americans has a condition doctors call Alcohol Use Disorder or AUD. If you have AUD, your choices and activities begin to be changed by your drinking habits. With so many people affected, we should call AUD an epidemic. Instead, most people suffer in silence. Because of that silence, we get a very warped impression of alcoholism. A few late stage cases, like the derelicts passed out in the streets, are hyper-visible, while the millions of early stage cases are invisible. Yet people avoid treatment out of fear of being stigmatized for AUD, and it's all due to visibility bias.

Alcohol abuse disorder must be treated effectively like any other disease. It's not a disease of the willpower. It's a chronic condition that arises when your brain reward systems get "hijacked" by the addictive substance. Some people's neurotransmitter systems are more vulnerable than others, and the more vulnerable ones get locked into the addiction cycle. It is neurotransmitter malfunction that locks in the addiction, and studies show that neural system recovery can take most of a year, depending on severity. Like any addiction, alcoholism continues to get worse if left untreated.

Most people have only two choices of treatment modality today: Alcoholics Anonymous, a support group which is available everywhere but not very effective; and Rehab, a residential dry out approach which is effective near-term but impossible for most people to use. Given these choices, it should be no surprise that so few of the 34 million AUD sufferers get any kind of treatment at all. Out of the big six chronic diseases, AUD stands alone in that barely 7% get treated each year.

What I find most surprising is that effective medical treatment has been available for almost 25 years without being broadly adopted by the medical profession. I am referring to "Medication-Assisted Treatment" with naltrexone, which has been tested and shown effective in multiple clinical trials. Why is this treatment not widely available today? What does it take to make this treatment available to everyone? Can a technology-enabled medical service company break through the barriers?

Speaker Bio

David is an entrepreneurial leader who has built four successful startups as founder, member of the board, and line executive in product development, sales, and business development.

As entrepreneur, he developed multiple products leveraging technology to provide new customer value in telecom, diagnostics, and medical devices; as angel investor he has coached dozens of technology companies from concept into commercialization.

David's business leadership includes recognizing market shifts in time to pivot the business focus, hiring standout teams from CEO through Engineer, managing IP portfolios leading to 62 issued patents, and leading an international team for four years in Europe; raised \$50 M from Tier-1 VCs and strategic partners; BS in Electrical Engineering, Massachusetts Institute of Technology and PhD in Physics, Stanford University.

WIB, Thursday Evening, March 16, 2017

Event: WIB-San Francisco Bay Area Women's History Month Event:
Leveraging Partnerships in the Growing Immuno-Oncology Space,
Date and Time: Thursday, March 16, 2017, 5:30 p.m. – 8:30 p.m. PST
Moderator: Stacy Feld, VP, Consumer Venture Investments & External Innovation,
J&J Innovation - JJDC
Panelists: Julie Hambleton, MD, VP and Head of US Medical, Bristol-Myers Squibb
Sylvaine Cases, PhD, VP of Oncology Scientific Innovation, Janssen R&D and J&J
Innovation; Jane Grogan, PhD, Head of Adaptive Tumor Immunity and Principal
Scientist, Genentech
Registration Deadline
March 13, 2017
Location: JLABS @ SSF, 329 Oyster Point Blvd., South San Francisco, CA 94080
Fees: Member - \$25 and Nonmember-\$55
Register at <http://womeninbio.org/eventdetails.aspx?EventId=30876>

Event Description

This event will feature women leading innovation, development, and growth through partnerships at life science companies. As biopharmaceutical companies seek to add novel candidates to their pipeline, immuno-oncology (pharmaceuticals that target the immune system to help fight cancer) has been an active area of focus for venture capital investment, partnerships, and collaborations in the life science sector. Although the immuno-oncology space is still nascent, there has been a steady flow of collaborations announced across a diverse range of deal structures.

Panelists will share their perspectives, experience, and lessons learned in evaluating and implementing immuno-oncology partnerships. Come and be inspired by these women leading the way in the biotech industry!

Participants will:

- Hear about trends in immuno-oncology
- Listen to industry leaders describe critical factors for successful partnerships
- Learn about partnership resource needs and life cycle as well as examples of building from synergies
- Be exposed to various types of collaborations and lessons learned in evaluating and implementing these partnerships.

Learn more and register for this event.

CABS, Saturday Afternoon, March 18, 2017

Topic: "NGS for cancer and autoimmune diseases"

Date and Time: Saturday March 18, 2017 @1:30 pm - 4:00 pm

Location: Genentech Building 31, 1531 Grandview Drive South San Francisco CA, 94080

(Note venue change with added capacity and earlier check-in & networking start time)

Cost: free

1:30-2:00PM check-in, onsite registration and networking

2:00PM-4:00PM

Register at

<http://www.cabsweb.org/events/2455515/NGS%20for%20cancer%20and%20autoimmune%20diseases/>

Program Description

Presentations:

- **Personalized health care for oncology** by Craig Cummings, Associate Director, Oncology Biomarker Development, Genentech
- **NGS application in immunology studies** by Naibo Yang, Director, Immunogenetics, Complete Genomics Inc.

EPPICon 2017, Saturday, March 25, 2017

Event: 11th Annual flagship event of EPPIC Global

Keynote Speakers: Ira Mellman, PhD (Genentech) and D. J. Patil (Chief Data Scientist, White House Office of Science and Technology)

Date and Time: Saturday, March 25, 2017,

8:00 AM: Registration open - Breakfast and Networking

9:00 AM: Opening / Plenary Keynote - Ira Mellman, PhD, Genentech

10:30 AM – 5:00 PM: Panels and Speakers

Location: Crowne Plaza Hotel San Francisco Airport, 1177 Airport Blvd, Burlingame, CA 94010

Registration online: \$100

On-site Registration: \$150

Student/Post Doc Registration Online: \$75* (Valid student ID to be presented at Conference)

EPPIC Charter Members** / Sponsors** / Event Speakers**

(Registration includes food and beverage - breakfast, lunch, coffee breaks and evening reception)

* Student/Post Doc promo code "STCON17"

** Renew or Register with Code provided to you: Conference is complimentary

Register at

<https://s07.123signup.com/servlet/SignUpMember?PG=1536045182300&P=15360451911431663100>

Visit www.eppicon.org for more information

Event Description

Since 1998, EPPIC Global has been serving the San Francisco Bay Area life sciences community promoting entrepreneurship, networking, partnering, and mentoring. Join us to hear expert talks and panel discussions on

Immunotherapy, Bioinformatics and Diagnostics

If targeted therapies and personalized medicine revolutionized cancer treatment in the last decade, will Immunotherapy be the next big hope during the coming decade?

Have we finally got a handle on big data and where is Bioinformatics headed?

Ditto with regard to Biomarkers and Diagnostics?

Advances in cancer immunotherapy have generated enthusiasm across all fields of oncology. Complimentary/companion diagnostics along with predictive biomarkers are integral to improving patient outcome. In addition, emphasis on personalized medicine and targeted therapies, diagnostics and biomarkers are playing an increasingly important role in drug development. Early adoption of bioinformatics tools can help advance therapeutic candidates.

EPPICon 2017 continues the grand tradition of bringing you the latest advances and opportunities in science and technology.

Get updated on the state of the art in science and business
Form new alliances
Explore investment opportunities

Who Should Attend

Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

OPEN for Registration NOW!!!

Click here to Register

Immuno-Oncology Panel: Chan Whiting, PhD, Aduro Biotech, Robert Sikorski, MD, PhD, Five Prime Therapeutics, Caroline Breitbach, PhD, Turnstone Biologics, Alex Franzusoff, PhD, PACT Pharma

Bioinformatics Keynote Speaker: Nikesh Kotecha, PhD

Bioinformatics Panel: Arshad Ahmad, Ajay Shah, Richard Bourgan, PhD, Genentech

Devices/Diagnostics: Speaker to be announced

Speed Pitch (Please see below for details)

11:30 AM – 1:15 PM: Speed Networking, Vendor Exhibit and Lunch

5:00 PM: Closing Keynote – D. J. Patil, Chief Data Scientist, White House Office of Science and Technology

Evening Reception and Networking

CABS, Saturday Afternoon, March 25, 2017

Topic: "Precision Medicine for oncology and immunology"

Date and Time: Saturday March 25, 2017 @ 2:00 pm - 4:00 pm

Location: Hanqi Investment, 1633 Bayshore Hwy, Unit 280, Burlingame, CA 94010

Free

Register at

<http://www.cabsweb.org/registration/2455518/Precision%20Medicine%20for%20oncology%20and%20immunology/>

Presentations:

1. Liquid biopsies in precision drug development by Shidong Jia, Founder and CEO of Predicine Holdings Ltd.

Cancer immunotherapy and targeted therapy offer great promise in precision oncology, where predictive biomarkers have been extensively investigated in various types of cancer patients. The talk will describe development and clinical application of an innovative, next generation sequencing based liquid biopsy test to support cancer immunotherapy clinical trials.

Speaker Bio

Dr. Shidong Jia is the Founder and CEO of Predicine Holdings Ltd, an international precision medicine organization that is committed to developing innovative diagnostics, therapeutics and big data in cancer and other serious diseases. The company operates in California, USA and Shanghai, China. Driven by a passion to improve personalized medicine, Dr. Jia has

dedicated the past 21 years to basic, translational, and clinical cancer research. His previous work identified p110beta as novel drug target for PTEN-deficient prostate tumors (Jia S, et al. Nature, 2008), a finding that laid the foundation for the clinical development and testing of p110beta inhibitors in cancers. Most recently, his team at Predicine developed world's first ctRNA and ctDNA combined liquid biopsy test for precision medicine in cancer. A former Scientist, principal investigator and prostate cancer disease area lead at Genentech, Dr. Jia spearheaded the biomarker strategies and drug & diagnostics co-developments efforts in support of clinical oncology pipeline at various stages (i.e., early stage research, late stage research, early clinical development, Phase I and Phase II clinical trials), culminated by the Lifecycle Investment Point (LIP) achievement of driving an investigative drug from global Phase II into Phase III pivotal clinical trial. Prior to joining Genentech, Dr. Jia was Laboratory Head for Oncology Drug Discovery at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Jia serves as the Editor-in-Chief of "Journal of Circulating Biomarkers", Guest Associate Editor of "Frontiers in Oncology", and Members of National Cancer Institute Review Committees and the Italian Ministry of Health - Scientific Research and Health Innovation Review Committee. Dr. Jia is a BayHelix member and receipt of several awards, including the "Young Investigator Award" at the Fourth Asian Congress for Microcirculation in Indonesia and the "P.A.R.T. Investigatorship Award" at the Dana-Farber Cancer Institute, Harvard Medical School in Boston.

2. Towards an Assay of Global Immunocompetence by Holden Maecker, Director, Human Immune Monitoring Center, Stanford

A long-term goal of our laboratory is to define metrics of healthy immune function and the deviations that predict or define disease states. There are many facets of the immune system that can be measured, and few clinically accepted tests of immune function. However, we hypothesize that a comprehensive assessment of the proportions, phenotypes, and functions of specific immune cell subsets in blood should be helpful in defining these metrics. We have therefore defined for this purpose a mass cytometry assay using phorbol myristate acetate (PMA)+ionomycin stimulation of peripheral blood mononuclear cells (PBMC), with staining for approximately 40 cell-surface and intracellular proteins, including lineage markers, cytokines, and other functional markers. Mass cytometry, or CyTOF, is a version of flow cytometry that uses heavy metal ion labels in place of fluorochromes, with readout by time-of-flight mass spectrometry. The CyTOF platform allows for many more labeled antibodies to be used in combination, with much less spillover between detection channels, compared to conventional flow cytometry. In this talk, I will describe this methodology and how we are applying it currently to the monitoring of patients undergoing cancer immunotherapy. Our goal in these studies is to better tailor immunotherapies to specific patients, and to suggest approaches that might be useful to address those patients with suboptimal immune function.

Speaker Bio

Dr. Holden T. Maecker received his PhD from Stanford University, is currently Assoc. Prof. at Microbiology & Immunology department and Director of Human Immune Monitoring Center at Stanford. His research is in the area of T cell response signatures and their association with protection from chronic pathogens and cancer. His lab has published a number of papers on this topic, both alone and in collaboration with other groups, in systems such as CMV, HIV, tuberculosis, and cancer. The Human Immune Monitoring Center (HIMC) is a Stanford core service laboratory, which performs blood processing and standardized assays using flow cytometry, genomics, and immunoassay platforms. For the past five years, his lab has gained extensive experience with CyTOF mass cytometry. In addition to being PI on multiple NIH, industry, and foundation grants, Dr. Maecker serves as a core leader for several cooperative center grants and other large collaborative projects, in which he oversees the use of HIMC assays, including data analysis and interpretation.

EPPICon, Saturday, March 25, 2017

Event: EPPICon 2017

Location: Crowne Plaza Hotel San Francisco Airport, 1177 Airport Blvd, Burlingame, CA 94010

Event Description

The 11th Annual flagship event of EPPIC Global, a San Francisco Bay Area based organization focused on pioneering advances in the life sciences and partnering, mentoring, and networking for professionals.

Featuring talks and panel discussions from leading experts on Immunotherapy, Bioinformatics and Devices

Who Should Attend

Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

Past Speakers at EPPICon

Kim Bush, Ann Lee, Corey Goodman, Hal Barron, James Sabry, Timothy Moore, Kiran Mazumdar-Shaw, Steven Isaacs and many more...

Stay tuned - Conference registration and additional information coming soon!

EPPICon 2017 Organizing Committee

EPPIC GLOBAL

www.eppicglobal.org

eppic@eppicglobal.org

(408) 357-0601

JLABS, Tuesday Morning, March 28, 2017

Topic: "Meet with ...MPM Capital"Program Overview:

Speakers: Vinay Bhaskar, Ph.D., Principal with MPM Capital;

Luke Evnin | Managing Director, MPM Capital

Date and Time: Tuesday, March 28, 2017, 10:30 am

Agenda:

10:30am | Registration & Networking

11:00am | Presentation and Q&A

11:45am | Lunch & Networking

12:30-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 28. Apply Here.

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco,

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until March 28th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on February 28, 2017. Your application will be reviewed and you will be notified of acceptance by March 15, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Registration at <https://www.eventbrite.com/e/meet-with-mpm-capital-tickets-29590468889?aff=weekly>

Topic Description

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas. MPM is no stranger to Johnson and Johnson Innovation, JLABS (JLABS) with investments that recently helped 3 Bay Area JLABS companies reach the next level. MPM is now investing two funds, BV2014, a \$400M fund focusing on early stage companies developing therapies for unmet medical needs (Series A and earlier), and the Oncology Impact Fund, a \$470M fund that invests solely in oncology companies of any stage (therapeutics only – no diagnostics). For more information on MPM visit <http://www.mpmcapital.com/>

Vinay Bhaskar, Ph.D., Principal with MPM Capital, will be in attendance to provide an overview presentation on MPM's key areas of interest and venture investment philosophy. Vin will be joined by Luke Evin to answer any questions and meet with a handful of applicants for one-on-one meetings. To be considered for a one-on-one meeting complete the information required in the link below.

About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas.

Speaker Bios

Luke Evin, Ph.D., co-founded MPM with Ansbert Gadick in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration and driving force behind building companies such as Biomarin (BMRN), CoStim

Pharmaceuticals (acquired by Novartis: NVS), Epizyme (EPZM), Idenix (acquired by Merck: MRK), Pacira (PCRX), Pharmasset (acquired by Gilead: GILD) and Radisu (RDUS). MPM believes that these companies are among the biggest successes in biotech history - companies that ultimately resulted in helping thousands of patients live longer with vastly improved lives. Luke was lead investor and has served on the boards of several of MPM's most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira.

Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke's passion for drug discovery began in college where he received his A.B. in Molecular Biology from Princeton University. He advanced his technical training and launched his interest in curing disease with his doctoral study in Department of Biochemistry at the University of California - San Francisco. Luke's passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team. Luke has devoted significant efforts since 2000 to working with Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, the Masters in Translation Medicine program at UCSF, and Boston University Scleroderma CORT.

Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck, and Xencor. During this time he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. Vin joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation, and diligence for licensing and acquisition opportunities on the Asset Acquisition Team. Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in Discovery Research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologies and spanned oncology, inflammation and cardio metabolic disease. Through these endeavors, Vin has gained broad expertise across all phases of drug discovery, early development and process sciences. Vin holds a Ph. D. in Biochemistry from UCLA and a B.S. in Biochemistry from UC Davis.

Biomedical Engineering Society, Wednesday, March 29, 2017

Event: 8th Annual Bay Area Biomedical Device Conference-Medical Devices in the Connected World

Date and Time: Wednesday, March 29, 2017, 7:30 am

Location: SJSU Student Union Ballroom, San Jose State University

Please take advantage of the reduced early registration which ends on March 16, 2017 at 5:00 pm. PST.

Visit our website at www.biomedconference.org for more details or email info@biomedconference.org if you have any questions.

Register at <http://www.biomedconference.org/register>

Event Description

The Biomedical Engineering Society at San Jose State University (SJSU) is happy to announce the 8th Annual Bay Area Biomedical Device Conference!

Some exciting features of this conference include:

- An expert biomedical plenary speaker
- Informative parallel sessions
- Interactive Industry & CEO Panels
- Student Research Posters
- Sponsors and representatives from various biomedical companies
- Wine & cheese networking reception
- & More!

PBSS Workshop, Thursday Afternoon, March 30 2017

Event: "Best CMC Practices for Successful Drug Development and Commercialization: Leveraging QbD and risk-based strategies for efficient CMC development"

Speakers: Prabu Nambiar, Edward Ciolkowski, James Bush (Syner-G Pharma Consulting)

Date and Time: Thursday, March 30, 2017, 12:30-5:00 pm Registration fee (US\$): Regular: \$125; Academic: \$75; For unemployed & students: \$25; For vendor-show reps: \$25; For major-sponsor rep (incl lunch): \$0; For others, details available upon online login.

Location: SF Bay Area: Foster City Crowne Plaza

Registration: <http://www.pbss.org/asp/EventInfo.aspx?eID=528>

Further Information:

Registration deadline: 3/28/2017 (it will close sooner if the seating cap is reached)

support@PBSS.org

www.PBSS.org

JLABS, Thursday, April 6, 2017

Event: MedTech Innovator 2017: JLABS Pitch Event

Date and Time: Thursday, April 6, 2017, 9:00 am – 5:00 pm

Agenda:

9:00am - 9:30am | Registration Opens and Networking

9:30am - 10:00am | Welcome & Introduction

10:00am - 12:30pm | Pitch Session (4 companies)

12:30-1:30pm | Networking Lunch

1:30pm - 4:00pm | Pitch Session II (4 companies)

4:00pm - 4:30pm | Success Stories Feature

4:30pm - 5:00pm | Award Presentation

*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.

Location: JLABS @ SSF, 329 Oyster Point Blvd., Floor 3, South San Francisco, CA 94080

Fees: Free

*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.

Apply Now to Pitch at JLABS

The MedTech Innovator SF Pitch Event is open to all attendees. Startups interested in pitching are encouraged to apply at <http://medtechinnovator.org/apply>.

See details at <https://www.eventbrite.com/e/medtech-innovator-2017-jlabs-pitch-event-tickets-31169197910?aff=weekly>

Event Description

About MedTech Innovator 2017

MedTech Innovator is the industry's nonprofit global competition and accelerator. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator is the largest platform of its kind, providing participants with broad exposure and mentorship from the leading players in the medtech industry. In 2017, MedTech Innovator will give out over \$500K in cash prizes.

MedTech Innovator Criteria

MedTech Innovator seeks early to mid-stage startups, including medical device, diagnostic, and digital health technologies addressing the following industry-selected themes:

Chronic Disease Management

Cognitive Devices and Platforms

Consumer Healthcare

Healthcare Efficiency and Cost Reduction

Infectious Disease Management

Next-Gen Surgical

Patient Safety and Satisfactio

Population Health; Precision and Personalized Medicine and Technology Enabled Services

Program Participant Benefits

Companies selected to participate in the MedTech Innovator Accelerator receive: Mentorship from leading investors, manufacturers, providers, payers, IP, regulatory and reimbursement professionals, and others.

Exclusive participation in the three-day MedTech Innovator Accelerator Kick-Off in San Francisco.

A chance to compete onstage for \$500,000 in cash prizes and more.

WIB, Wednesday Evening, April 12, 2017

Subject: WIB-National Webinar "Risky Business: Mitigating Risk in the Life Sciences"

Speaker: Gretchen Stup, Sr. Consultant at Latham Biopham Group

Date and Time: April 12, 2017, 1:00 p.m. – 2:00 p.m. EST*

*- Please note this webinar's time is listed in Eastern Standard Time.

Pricing Information

Members: Free

Non-Members: \$30

* - Registrants will be sent a specific GoToMeeting link to access the webinar. Please be sure to click on the link before the webinar to ensure the program is properly installed on your computer.

Register at <http://womeninbio.org/eventdetails.aspx?EventId=30877>

Registration Deadline

April 11, 2017

Registrants will receive a webinar link via confirmation email

Webinar Description

Inviting. Supporting. Succeeding.

All projects present risk, and successful project managers recognize that it is vital not to avoid risks, but to understand them. Risk management is the process of identifying, assessing, mitigating, and controlling the known risks in order to increase the probability of meeting your project objectives. By planning for unexpected events, you can be ready to respond if they arise. This webinar will be led by Gretchen Stup, Senior Consultant, Latham BioPharm Group, and will bring to light the importance of Risk Management as well as introduce methods and tools that can be implemented to ensure a successful risk management process. Gretchen will utilize a slide presentation and will review specific examples to help illustrate the key concepts of Risk Management. The presentation will help you understand how to identify what can go wrong, how to assess a risk events probability and impact, and what to do to lessen the probability or impact of a risk event occurring. Real-world examples and considerations from the speaker's professional experience will be highlighted during the webinar. In addition, there will be time allotted for questions and answers at the conclusion of the webinar.

This course will result in up to one hour of PMI-approvable Professional Development Units (PDUs) for the project management field.

Learn more and register for this event.

Speaker Bio

About Gretchen Stup: Gretchen has over 16 years of experience in the management of government contracts, and over 18 total years of experience working in a scientific environment. She is currently a Sr. Consultant at Latham Biopharm Group where she provides program management and systems integration support to government and client related projects. Prior to this, she served as a Sr. Project Manager for DynPort Vaccine Company (DVC) where she managed a >\$350 M DoD advanced vaccine development contract and a smaller NIAID R&D contract. She has experience in total project lifecycle management, with a focus on managing and integrating the activities of numerous functional areas, including finance, manufacturing, nonclinical, quality, clinical, and regulatory personnel, and managing project related subcontractors. Prior to working in Program Management, Gretchen co-developed and implemented DVC's comprehensive Risk Management program. She has a Bachelor of Science degree from Shepherd University and is a Project Management Professional (PMP) as certified by the Project Management Institute.

Walk-Ins Accepted?

Walk-ins are not accepted – be sure to register early!

JLABS, Tuesday Morning, April 18, 2017

Topic: "Meet with the Gates Foundation"

Speaker: Charlotte Hubbert, PhD | Partner, Gates Foundation Venture Capital

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Date and Time: Tuesday, April 18, 2017, 10:30 am

Agenda:

10:30am | Registration & Networking

11:00am | Company Presentation and Q&A

11:45am | Lunch & Networking

12:45-5:00pm | One-on-one Meetings*

*Companies must have apply ahead of time and be approved for a one-on-one meeting. Application period ends March, 13, 2017. Apply Here.

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until 12:30pm on April 18th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on March 13, 2017. Your application will be reviewed and you will be notified of acceptance by March 30, 2017. Acceptance of one-on-one meeting is not guaranteed as all applications must be approved

Registration at <https://www.eventbrite.com/e/meet-with-the-gates-foundation-tickets-29533732188?aff=weekly>

Program Overview:

The path out of poverty is paved with access to quality healthcare. Do you have solutions that will make a difference? The Bill & Melinda Gates Foundation is advancing science and technology to save lives in developing countries. The Foundation works with partners to deliver proven tools—including vaccines, drugs, and diagnostics—and discover ground breaking new solutions that are affordable and reliable. Focus areas for investments center on infectious diseases including HIV, polio, TB, dengue and malaria, as well as diagnostics and health IT ideas that bring health interventions to people who need them most.

Charlotte Hubbert, Partner with Gates Foundation Venture Capital, will be in attendance to provide an overview presentation on the Foundation's key areas of interest and venture investment philosophy. Gates Foundation Venture Capital operates under the Program Related Investments group at the Bill & Melinda Gates foundation, which manages a \$1.5B allocation for private sector investment. Charlotte will be on hand to meet with a handful of applicants one-on-one after the presentation. To be considered for a one-on-one meeting complete the information required at the link below.

Speaker Bio

Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing innovative technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.

Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-

doctoral work in stemcells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).
Connect with Charlotte: Connect on LinkedIn

About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

PBSS Symposium, Monday, April 24, 2017

Topic: "Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK Scientists"

Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)

Date and Time: April 24, 2017, 8:45-17:00

Location: Crowne Plaza, Foster City, CA

Registration fee (USD): Minisymposium fee: \$195;

Registration: <http://www.PBSS.org>

Registration deadline:4/20/2017 (it will close sooner if the seating cap is reached)

Topic Description

Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.

Tentative topics and speakers:

Morning: 8:45-12:00

Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech

Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS
Sponsor presentation

Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck

Prediction of circulating drug metabolites - Ming Hu, University of Houston

Afternoon: 1:15-5:00

Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech

Sponsor presentation

Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech

Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid of target hepatotoxicity - Raju Subramanian, Gilead

Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech

Carboxylic acid bioactivation via glucuronides/acyl CoA's and application in drug discovery – Mark Grillo, Amgen

JLABS Bay Area, Tuesday Mid Day, May 2, 2017

Topic: "Money Matters - Insider Tips on Raising Money"

Speaker: Julie Papanek, Partner, Canaan Partners

Date and Time: Tuesday, May 2, 2017, 10:30 am – 1:00 pm

Agenda:

10:30 AM | Registration and Networking

11:00 AM | Presentation

11:30 AM | Q&A

12:00 PM | Food and Networking

1:00 PM | Program Close

Fees:

\$25 | General Public

\$15 | Student

\$45 | At the door

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Order at <https://www.eventbrite.com/e/money-matters-insider-tips-on-raising-money-tickets-32167293240?aff=weekly>

Speakers Bio

Julie Papanek is a Partner at Canaan Partners where she concentrates on biopharmaceutical, digital health and consumer medical device investments. Julie currently sits on the board of Protagonist Therapeutics (PTGX) and has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development.

Julie earned her MBA from Stanford's Graduate School of Business, MPhil from Cambridge in BioScience Enterprise and B.S. from Yale in Molecular Biophysics and Biochemistry.

JLABS, Tuesday Morning, May 23, 2017

Topic: "Rough seas or smooth sailing? Navigating Collaboration Agreements"

Speakers:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation

William J. Newell | CEO, Sutro Biopharma

Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS

Date and Time: Tuesday, May 23, 2017 from 9:00 AM to 11:30 AM (PDT)

Agenda:

9:00 AM | Registration, Breakfast, and Networking

9:30 AM | Components of a collaboration agreement

10:00 AM | Panel Discussion: Implications of Components

11:00 AM | Q&A

11:30 AM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees:

\$25 | General Public

\$15 | Student

Order at <https://www.eventbrite.com/e/rough-seas-or-smooth-sailing-navigating-collaboration-agreements-tickets-32071988180?aff=weekly>

Event Details

How do you develop a smart collaboration agreement? An effectively written collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship.

How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.

At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk will provide real world examples and focus on the following topics:

Intro to Collaboration Agreements / General provisions

Statement of objectives/work

Budget

IP

Restrictions and opportunities created by agreements

Real world examples from panel members

The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup

Guests will be provided supporting materials including:

Key provisions guide

Sample Collaboration agreements

This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to...Workshop" is informal and interactive so bring your questions with you!

Speakers' Biographies:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.
Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.
Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted

postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
